PandaOmics
Insilico Medicine
AI-driven target identification and biomarker discovery platform. Processes omics data, text mining, and knowledge graphs to prioritize novel therapeutic targets. Core component of Insilico's Pharma.AI suite alongside Chemistry42 and inClinico.
Best For
AI-driven target identification with integrated omics analysis; aging and fibrosis targets
License
Commercial
Strengths
- +Multi-omics integration
- +Proprietary AI target scoring
- +Clinical validation (ISM001-055 from PandaOmics target)
- +Integrated with Chemistry42
Limitations
- −Fully proprietary
- −Expensive licensing
- −Black-box scoring algorithms
R&D Pipeline Coverage
Related Tools
Chemistry42
Insilico Medicine
Commercial generative chemistry platform using an ensemble of deep learning architectures. Part of the Pharma.AI platform. Has molecules in Phase I/II clinical trials.
Open Targets Platform
EBI / Genentech / GSK / MSD / Pfizer / Sanofi / Wellcome Sanger
Integrates 23+ public data sources to systematically score and rank target-disease associations. Provides target prioritization based on clinical precedence and tractability.
DisGeNET
IMIM / DisGeNET (commercial entity)
Comprehensive gene-disease and variant-disease association database. >2M GDAs, >4M VDAs, >20M DDAs. Integrates curated repositories, GWAS, animal models, and NLP-extracted evidence.
More in Target Discovery
Open Targets Platform
EBI / Genentech / GSK / MSD / Pfizer / Sanofi / Wellcome Sanger
Integrates 23+ public data sources to systematically score and rank target-disease associations. Provides target prioritization based on clinical precedence and tractability.
DisGeNET
IMIM / DisGeNET (commercial entity)
Comprehensive gene-disease and variant-disease association database. >2M GDAs, >4M VDAs, >20M DDAs. Integrates curated repositories, GWAS, animal models, and NLP-extracted evidence.
STRING v12.5
EMBL / SIB / CPR
Functional protein-protein association networks across 12,535 organisms. v12.5 added a regulatory network layer capturing directionality via LLM-parsed literature.
Stay updated on PandaOmics
Weekly newsletter covering AI tool releases, benchmarks, and what practitioners actually use.